Background: In the ANRS 165 DARULIGHT study (NCT02384967) carried out in HIV-infected patients, the use of a darunavir/ritonavir-containing regimen with a switch to a reduced dose of darunavir maintained virological efficacy ( 50 copies/mL) for 48 weeks with a good safety profile.
Introduction
Over the past two decades, the life expectancy of patients living with HIV has significantly increased, which can be mainly ascribed to the potency of highly active antiretroviral regimens and better tolerability. 1 For many HIV-infected individuals, their infection has now been transformed into a chronic manageable disease. At the time of study design conception, the most common highly active antiretroviral regimen recommended worldwide was a backbone combination of two NRTIs associated with a third antiretroviral V C The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com. drug, with a preference for a PI boosted with ritonavir. Achieving sustained virological suppression remains a challenge for many HIV-infected patients, while the risks and potential adverse events associated with long-term ART have become a major issue. In this respect, several strategies have been proposed aimed at reducing the antiretroviral dosing regimen without jeopardizing its efficacy and future treatment options. Antiretroviral dose reduction based on pharmacokinetic parameters is such a strategy of treatment lightening. 2, 3 Furthermore, dose reduction might also increase the cost-effectiveness of treatment.
Ritonavir-boosted darunavir (darunavir/ritonavir) is one of the most widely prescribed PIs and is the preferred PI in USA and European guidelines 4, 5 as a once-daily (q24h) ART combination for both naive and antiretroviral-experienced patients with no previous darunavir-associated substitution. A recent study comparing 800/100 and 600/100 mg darunavir/ritonavir q24h showed no difference in efficacy or drug plasma exposure, suggesting a nonlinear dose-concentration relationship. 6 The ANRS 165 DARULIGHT trial was a 48 week, prospective, multicentre, Phase II open label trial. The study protocol was registered on clinicaltrials.gov (NCT02384967) and was approved by our institutional ethics committee (AP-HP, Hôpital Saint Louis, Paris, France). The main objective was to evaluate the efficacy and safety of a dose reduction of darunavir/ritonavir [400/100 mg q24h at week (W) 48] in HIV-1 infected patients with blood plasma HIV-1 RNA 50 copies/mL receiving darunavir/ritonavir (800/100 mg q24h) associated with two NRTIs. 7 A total of 100 patients were enrolled, including 15 patients for the pharmacokinetic sub-study.
The aim of this sub-study was to assess the total (darunavir, ritonavir and NRTIs) and unbound blood plasma pharmacokinetic parameters of darunavir before and after switching to the reduced dose. The secondary objectives were to assess the pharmacokinetics of the associated NRTIs using non-compartmental analysis in both dosing regimens and the penetration of antiretrovirals into seminal plasma.
Patients and methods

Study population
The criteria for inclusion were those of the ANRS 165 DARULIGHT trial, namely: HIV-1 infection, age !18 years, receiving darunavir/ritonavir (800/100 mg q24h) as part of their ART, associated with two NRTIs for at least 6 months, plasma HIV-1 RNA 50 copies/mL for at least 12 months and no documented darunavir-or NRTI-associated substitutions. For the pharmacokinetic sub-study, only male patients were recruited for the assessment of the penetration of antiretrovirals into seminal plasma. Co-medications were permitted only if there was no clear interaction according to the respective label information. All patients were considered to be at steady-state at study initiation (W0) and W12 after treatment switch to 400/100 mg darunavir/ritonavir q24h. Patients were instructed to take daily darunavir/ritonavir (one 800 mg tablet of darunavir at W0 and one 400 mg tablet of darunavir after W0 plus one 100 mg tablet of ritonavir) with food in the morning in combination with two NRTIs (one 200/300 mg tablet of emtricitabine/tenofovir disoproxil fumarate or 600/300 mg of abacavir/lamivudine).
Blood and seminal plasma drug determination
For the intensive plasma pharmacokinetic analysis, blood samples were drawn pre-dose and at 1, 3, 5, 8 and 24 h after the last drug intake. Trough sperm samples were collected by self-masturbation for 15 patients at W0 and W12 after at least 3 days of abstinence. Total (darunavir and ritonavir and NRTIs) and unbound (darunavir only) blood and seminal plasma concentrations of antiretrovirals were determined by LC-tandem MS (Waters Acquity UPLC-TQD, Milford, MA, USA). 8 Blood and seminal plasma protein-binding analysis involved an ultrafiltration assay (Centrifree V R ; Millipore, Molsheim, France; 2000 g for 30 min). The limit of quantification (LOQ) was 5 ng/mL for darunavir, emtricitabine, tenofovir, abacavir and lamivudine, and 10 ng/mL for ritonavir.
Population pharmacokinetic modelling of darunavir and ritonavir plasma concentrations
A non-linear mixed-effects modelling approach was applied for total (darunavir and ritonavir) and unbound (darunavir only) plasma concentrations at W0 and W12 separately using a stochastic approximation of expectation maximization (SAEM) algorithm implemented in Monolix Suite (2016R1; http://lixoft.eu; Lixoft, Paris, France). First, the structural model was selected (one-compartment versus two-compartment models for distribution and the presence/absence of a lag time for the absorption phase). Additive, proportional and combined variance models were then compared for residual errors, and finally the presence/absence of inter-individual variability was assessed using a backward strategy, removing random effects on each structural model parameter sequentially.
Once the structural, residual error and random effect models were selected to describe total plasma concentrations, unbound concentration data were then added to the data set as a second output (i.e. as a fraction, f u , of the total concentration).
Model selection was performed based on Bayesian information criteria and model evaluation [adequate goodness-of-fit (GOF) plots, n " 500 Monte Carlo simulation replicates] and low relative standard error (RSE) of pharmacokinetic parameter estimates.
Bioequivalence testing for darunavir after/before treatment switch At W0 and W12, individual parameters of pharmacokinetic empirical Bayes estimates were derived and the corresponding shrinkage estimates calculated. Respective AUC 0-24 values were derived directly from the individual clearance estimates and plasma C max from model predictions.
Bioequivalence for darunavir AUC 0-24 and C max was declared when the 90% CI for the geometric mean ratio (GMR) of after versus before the switch (W12/W0) fell within 80%-125%. 9 Blood plasma darunavir C min values were interpreted according to the 10-fold in vitro median effective concentration corrected for protein binding required to induce a 50% virological response (EC 50 ) of 550 ng/mL. 10 Non-compartmental analysis of plasma NRTIs and seminal darunavir, ritonavir and NRTI concentrations Pharmacokinetic parameters were first calculated from the NRTI plasma concentration-time data using non-compartmental analysis (R version 3.3.2, https://cran.r-project.org/). For each patient and for all NRTIs, C min , C max and total plasma AUC 0-24 were obtained. C min was defined as the lowest plasma concentration observed within the dosing interval of 24 h. AUC 0-24 was determined using the composite trapezoid rule; elimination t1 =2 was calculated using linear regression of concentration-time data after T max (5, 8 and 24 h ). Total seminal NRTI and darunavir trough concentrations (C trough ) were also determined. Seminal plasma darunavir C trough was interpreted according to the EC 50 of 55 ng/mL on WT HIV-1. 10 Population modelling of low-dose darunavir/ritonavir JAC Ethics Written informed consent for the pharmacokinetic sub-study was obtained in addition to informed consent to participate in the main study. The study protocol was reviewed and approved by the Paris Saint-Louis Ethics Committee (Comité de Protection des Personnes) and Health Authority (EudraCT number 2014-001505-40) and was conducted in accordance with the Declaration of Helsinki.
Statistical analysis
The results are presented as median (IQR) and GMR (using log-transformed values) with 90% CI for the different pharmacokinetic parameters at W0 and W12 (W12/W0). Statistical comparisons (using linear values) were performed using the Wilcoxon test on paired data and Fisher's exact test. Significance was determined at P , 0.05.
Results
Study population
In this ANRS 165 DARULIGHT pharmacokinetic sub-study 15 patients (all male) were included, corresponding to 15 sets of paired data between W0 and W12. The median age was 42 years (41-47). Among the 15 patients, 12 received darunavir/ritonavir associated with emtricitabine/tenofovir disoproxil fumarate and three received darunavir/ritonavir associated with abacavir/lamivudine.
Population pharmacokinetic modelling of darunavir and ritonavir
A two-compartment model with first-order absorption and lag time provided the best description of total and unbound blood plasma concentrations of darunavir. An exponential random effect model was selected. Estimated pharmacokinetic parameters are shown in Table 1 . Inter-individual variances were estimated for all parameters except for the apparent central volume of distribution of darunavir, with F as bioavailability (V c_DRV /F DRV ) in the 400/ 100 mg q24h dosing regimen (at W12). For the ritonavir concentration, a one-compartment model with a lag time in absorption best fitted the total blood plasma data. Unbound blood plasma concentrations of ritonavir could not be assessed, probably due to its high protein-binding profile and the sensitivity of our bioanalytical assay; all concentrations were below the LOQ. The pharmacokinetic parameter estimates are shown in Table 2 . Inter-individual variances were estimated for all parameters except the V/F value for ritonavir (V RTV /F RTV ) in the 400/100 mg darunavir/ritonavir q24h dosing regimen (at W12). All shrinkage values for darunavir and ritonavir parameters were ,20%.
Model diagnostics
GOF plots (normalized prediction distribution error versus time) for total and unbound blood plasma darunavir and total blood plasma ritonavir are shown in Figures 1 and 2 . All the GOF plots indicate a good predictive performance of the model and even the worst individual predictions were satisfactory.
Bioequivalence approach
Median (IQR) AUC 0-24 for total darunavir was 65563ngÁh/mL (45149-74669) and 52518 ngÁh/mL (46015-96107) at 800/100 and 400/100 mg q24h, respectively. The AUC 0-24 for total ritonavir was 4080 ngÁh/mL (3312-5241) and 5581 ngÁh/mL (4405-6412) at 800/100 and 400/100 mg q24h, respectively ( Table 3 ). The 90% CI for AUC and C max GMR were not included within the 80%-125% interval so we could not make any conclusions about Lê et al. Figure 1 . Observed concentrations (circles) and best (left column) and worst (right column) individual predictions of blood plasma concentrations versus time for total (a and b) and unbound (c and d) blood plasma darunavir at the 800/100 mg q24h dose, total (e and f) and unbound (g and h) blood plasma darunavir at the 400/100 mg q24h dose and total ritonavir at 800/100 mg q24h (i and j) and 400/100 mg q24h (k and l) doses.
Population modelling of low-dose darunavir/ritonavir JAC bioequivalence of the two dosing regimens for darunavir and ritonavir (Table 3) . Moreover, in our analysis, no significant difference could be demonstrated in blood plasma AUC 0-24 , C max and C min for darunavir, whereas blood plasma AUC 0-24 and C max for ritonavir were higher at W12 than W0 (Table 3) .
Non-compartmental analysis
The proportion of patients with total blood plasma C min for darunavir below the 550 ng/mL threshold (10-fold EC 50 ) 10 was similar at W0 (n " 1) and W12 (n " 3) (P " 0.13; Fisher's exact test). For the different NRTIs, total blood plasma C min , C max , t 1/2 and AUC 0-24 and Figure 2 . Normalized prediction distribution error (NPDE) versus time and versus predictions for the final model of total (a) and unbound (b) blood plasma darunavir at the 800/100 mg q24h dose, total (c) and unbound (d) blood plasma darunavir at the 400/100 mg q24h dose and total ritonavir at 800/100 mg q24h (e) and 400/100 mg q24h (f) doses, from Monte Carlo simulation replicates (n " 500). Lower, middle and upper shaded areas represent the 95% model prediction intervals associated with the 10th, 50th and 90th percentiles, respectively. The lines represent the corresponding empirical percentiles.
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seminal plasma C trough are shown in Table 4 and Figure 3 . No significant difference was reported in total blood plasma exposure of NRTIs between W0 and W12, or in the darunavir, ritonavir and NRTI t1 =2 . The ratios of total seminal plasma/total blood plasma antiretroviral concentrations are shown in Figure 3 . No significant difference was reported in seminal unbound fraction of darunavir between W0 and W12 (P " 0.28). The ratios of total seminal/unbound blood plasma concentrations of darunavir were 1.39 (1.09-2.71; n " 11) and 1.68 (1.46-2.28; n " 9) at W0 and W12, respectively (P " 0.99). There was no significant difference in the proportion of unbound seminal plasma concentrations of darunavir .55 ng/mL (EC 50 ) 10 between W0 (n " 9) and W12 (n " 5) (P " 0.36; Fisher's exact test).
Discussion
In our study, total and unbound blood plasma concentrations of darunavir were consistent with the virological (91.6% success rate; Table 3 . Model-based AUC 0-24 (ngÁh/mL), C max and C min (ng/mL) and t1 =2 (h) estimates for blood plasma darunavir (total and unbound) and ritonavir for darunavir/ritonavir 800/100 mg q24h (W0) and 400/100 mg q24h (W12) dosing regimens and corresponding W12/W0 GMR (90% CI) n, number of patients. Bioequivalence was assessed by comparing the GMR 90% CI with the EMA bioequivalence range of 80%-125%. Table 4 . Non-compartmental C min (ng/mL), C max (ng/mL), AUC 0-24 (ngÁh/mL) and t1 =2 (h) estimates of total blood plasma emtricitabine (200 mg q24h), tenofovir (300 mg q24h), abacavir (600 mg q24h) and lamivudine (300 mg q24h) for darunavir/ritonavir dosing regimens of 800/100 mg q24h (W0) and 400/100 mg q24h (W12) and corresponding W12/W0 GMR (90% CI) Population modelling of low-dose darunavir/ritonavir JAC 95% CI 84.1%-96.3%) and safety results of the ANRS 165 DARULIGHT study. 7 Indeed, most of our patients had blood and seminal plasma concentrations above the respective efficacy thresholds of 550 and 55 ng/mL, respectively. Furthermore, we did not observe any difference in total blood plasma exposure of darunavir even with a 50% decrease in the daily dose. However, bioequivalence between the two darunavir dosing regimens could not be demonstrated. Our darunavir model and exposure results at W0 (darunavir/ritonavir dosing regimen of 800/100 mg q24h) were consistent with previous studies. 6, 11, 12 However, they were slightly lower than in patients receiving a darunavir-containing regimen for the first time (POWER and ARTEMIS trials). 10, 13, 14 A decrease in darunavir plasma exposure over time was described, probably due to auto-induction of darunavir metabolism. 15 Moltó et al. 6 compared total blood plasma exposure of darunavir between darunavir/ritonavir regimens of 800/100 and 600/100 mg q24h (DRV600 study). These authors reported no significant decrease in total blood plasma darunavir AUC 0-24 with a 25% dose reduction. Although a bioequivalence assay through the population approach is deemed more powerful, 9 this approach was not conclusive here. This result might be explained by the large random effect variances of darunavir pharmacokinetic parameters. Unfortunately, our study was not originally designed to assess bioequivalence of such a dose reduction, which is probably better assessed with an adequate study design reflecting the different doses and interactions. Indeed, the 80%-125% range could have been widened because of the high within-patient variability of darunavir and a higher number of patients would probably increase the power to report a significant decrease in AUC, C max or C min of darunavir at the 400/100 mg q24h dose. 16 The pharmacokinetics of unbound blood plasma concentrations of darunavir were also analysed, with no difference in exposure but with a slight decrease in C max between W0 (800/100 mg q24h) and W12 (400/100 mg q24h) [GMR (90% CI) 0.83 (0.68-0.99)] ( Table 3 ). The ratio of unbound/total blood plasma exposure of darunavir also decreased slightly between W0 and W12 (Table 3 ). In addition, ritonavir AUC 0-24 was significantly increased with the dose reduction of darunavir. However, it was not considered to be clinically relevant, with no changes in the occurrence of treatment-related adverse events.
Our results for darunavir and ritonavir pharmacokinetic parameters with the two dosing regimens may be explained mechanistically by a change in the daily dose balance of darunavir/ritonavir (800/100 to 400/100). Indeed, ritonavir is used here as a pharmacokinetic enhancer. It is mainly a substrate of CYP3A4 and CYP2D6 and is transported by P-glycoprotein (P-gp); it is an inhibitor of CYP3A, CYP2D6 and P-gp, and an inducer of CYP1A2, CYP2C8, CYP2C9 and CYP2C19 expression. 17 Darunavir metabolism and drug interaction pathways are often underestimated and reduced to CYP3A, whereas darunavir is a substrate of CYP3A4 and is transported by P-gp: it is an inhibitor of CYP3A4, CYP2D6 and P-gp, and an inducer of CYP2C9, CYP2C19 and CYP2C8. 16 With the decrease in darunavir dose, the induction of ritonavir might be reduced and explain the slight increase in ritonavir AUC 0-24 and C max at W12. Lê et al.
Our results highlight the complexity of darunavir pharmacokinetics, its non-linear dose-concentration relationship and the multidirectional interaction between darunavir and ritonavir, justifying the modelling of darunavir and ritonavir at the two doses separately. The darunavir/ritonavir balance appeared to have a significant impact on both blood and seminal compartments. Indeed, the impact of the dosing regimen on both total blood plasma CL/F of darunavir and ritonavir but also on darunavir transfer from the central to the seminal compartment reflects the impact of the balance between the darunavir and ritonavir daily dose on CYP and the efflux transporter. Both Arab-Alameddine et al. 18 and Moltó et al. 19 presented data with both the absorption constant and the elimination constant, showing comparable values for both darunavir and ritonavir. At first glance, these results suggest a potential 'flip-flop', which should mostly be observed for galenic formulations presenting a slow absorption rate as long-acting drugs (i.e. nanoparticles). Nevertheless, the interaction between darunavir and ritonavir might impact on bioavailability (F), which cannot be captured with 'only' blood plasma concentrations from oral administration at steady-state. Moreover, the interaction models between darunavir and ritonavir and simulation of pharmacokinetic data at different doses were only described from a data set obtained at a fixed dose of darunavir/ritonavir. Thus, simultaneous modelling and external comparisons with the Arab-Alameddine et al. 18 and Moltó et al. 19 studies are difficult to conduct. In our study, the total blood plasma AUC 0-24 of the NRTIs (emtricitabine, tenofovir, abacavir and lamivudine) at W0 were consistent with previous results. [20] [21] [22] Moreover, no significant modification was observed after reducing the daily dose of darunavir, suggesting no or only a mild effect of the modified darunavir/ritonavir balance on NRTIs, in particular the drug interaction between ritonavir and tenofovir. 23 Indeed, ritonavir is an inhibitor of multidrug resistance protein 4 (MRP-4) and MRP-2 and might decrease the secretion of tenofovir into the renal tubular lumen. 23 Concerning the seminal compartment, no significant difference was reported in total unbound seminal plasma concentrations of darunavir between W0 and W12. An increase in the unbound ratio of darunavir in seminal plasma was observed due to its different protein composition in comparison with blood plasma. 24 Median ratios of total seminal/unbound blood plasma concentrations were .100% at both W0 and W12, suggesting a good distribution of the unbound fraction of darunavir in the seminal compartment, probably associated with accumulation. Moreover, most total and unbound seminal plasma concentrations of darunavir remained above the EC 50 , suggesting that local darunavir contributes to antiviral efficacy against WT viruses. The emtricitabine/tenofovir ratio of total seminal plasma/total blood plasma concentrations was similar for the two darunavir/ritonavir dosing regimens. Overall, these results were expected because the respective NRTI doses were not modified. Furthermore, the NRTIs penetrated well into the seminal compartment, which might support the efficacy of a reduced dose regimen at this site.
Conclusions
In our study of HIV-1-infected patients switching from a regimen containing 800/100 mg darunavir/ritonavir q24h to a regimen containing 400/100 mg darunavir/ritonavir q24h as maintenance treatment (ANRS 165 DARULIGHT trial), no bioequivalence of total and unbound blood plasma exposure of darunavir between the two dosing regimens was observed. Modification of the darunavir/ ritonavir balance suggests no or only a mild impact on NRTI distribution (i.e. tenofovir). These pharmacokinetic results, associated with the efficacy, safety and tolerance results, support the continued investigation of a dose reduction of darunavir to 400/100 mg q24h in HIV-infected patients as maintenance treatment.
